Publicacions en col·laboració amb investigadors/es de Clínica Universitaria de Navarra (110)

2024

  1. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial

    Heart

2023

  1. Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials

    Journal of Sport and Health Science, Vol. 12, Núm. 2, pp. 147-157

  2. Practical approaches to building up a cardiorenal clinic

    Clinical Kidney Journal, Vol. 16, Núm. 5, pp. 780-792

  3. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Circulation: Heart Failure, Vol. 16, Núm. 5, pp. E009694

  4. Revisiting skeletal myopathy and exercise training in heart failure: Emerging role of myokines

    Metabolism: Clinical and Experimental, Vol. 138

2022

  1. Heart failure in chronic kidney disease: The emerging role of myocardial fibrosis

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 5, pp. 817-824

  2. Management of cardiac fibrosis is the largest unmet medical need in heart failure

    Cardiovascular Research

  3. The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure

    Clinical Kidney Journal, Vol. 15, Núm. 5, pp. 865-872

  4. Transition to heart failure in hypertension: going to the heart of the matter

    European heart journal

2021

  1. Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 41, Núm. 4, pp. 391-402

  2. Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology

    Nefrologia, Vol. 41, Núm. 4, pp. 391-402

  3. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

    Nature Reviews Cardiology, Vol. 18, Núm. 7, pp. 479-498

  4. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension

    JACC: Basic to Translational Science, Vol. 6, Núm. 1, pp. 12-21

  5. Heart failure-related skeletal myopathy. Potential involvement of myokines

    Revista Espanola de Cardiologia, Vol. 74, Núm. 12, pp. 1009-1013

  6. Identification of sex-specific biomarkers predicting new-onset heart failure

    ESC Heart Failure, Vol. 8, Núm. 5, pp. 3512-3520

  7. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

    Frontiers in Cardiovascular Medicine, Vol. 8

  8. Setting up a cardiorenal clinic. Consensus document of the cardiorenal working groups of the Spanish Society of Cardiology and the Spanish Society of Nephrology

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 284-295

  9. The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy – A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy

    European Journal of Heart Failure, Vol. 23, Núm. 6, pp. 933-944

  10. The need for a cardionephrology subspecialty

    Clinical Kidney Journal, Vol. 14, Núm. 6, pp. 1491-1494

2020

  1. Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696)

    Scientific Reports